Introduction
Swiss pharmaceutical market entry is one of the most patent-intensive product launch decisions a pharma company can make. Switzerland is home to Novartis and Roche — two of the world’s largest patent-holding pharmaceutical companies — alongside dozens of specialty pharma, biotech, and medtech companies with significant domestic and international patent portfolios. The blocking IP picture for a Swiss pharma product launch has three dimensions that most international FTO analyses handle incompletely: the EPO patent layer, the domestic IPI patent layer, and the SPC extension layer.
Getting all three dimensions right is not just a thoroughness question. It is a commercial question. An SPC that extends protection on a key compound patent by five years represents five additional years of market exclusivity for the originator. A generic or biosimilar manufacturer that misses an active SPC in its FTO — or that treats SPC validity as equivalent to underlying patent validity without a separate assessment — may launch into blocked territory without understanding the full extent of the clearance problem.
This article covers the two-layer structure of Swiss pharma FTO, how SPC extensions work in Switzerland, why SPC validity requires a separate assessment from underlying patent validity, and how to build a complete Swiss pharmaceutical FTO that accounts for all three dimensions.
The Two Layers of Swiss Pharma FTO That Both Require Coverage
The Swiss patent landscape has two structurally distinct layers that together define the full IP picture for a pharmaceutical product. As our analysis of what Switzerland’s Patent Act revision means for IP landscape strategy covers, most competitive IP analysis focuses on the EPO layer and systematically underweights the domestic Swiss patent layer. For pharma FTO, this gap is commercially material.
Layer 1: EPO-Granted Patents Validated in Switzerland European patents granted by the EPO can be validated in Switzerland through the standard EPO national phase process. These patents are governed by Swiss law for infringement and validity purposes, litigated before the Swiss Federal Patent Court, and assessed at EPO-comparable claim scope. This is the layer most international FTO analyses cover. It is necessary but not sufficient.
Layer 2: Domestic IPI-Granted Swiss Patents Switzerland has its own domestic patent system administered by the Swiss Federal Institute of Intellectual Property (IPI). Swiss domestic patents are separate rights from EPO-validated European patents — not equivalent, not interchangeable. Major Swiss pharma companies including Novartis and Roche hold significant domestic Swiss patent portfolios covering compound variants, formulation methods, manufacturing processes, and combination therapy approaches. An FTO that covers only EPO-validated patents misses this layer entirely.
Why the domestic layer is frequently underweighted: International FTO teams unfamiliar with Switzerland often treat EPO patent coverage as comprehensive for the Swiss market. It is not. The domestic IPI layer represents a distinct body of patent rights that requires separate searching of the IPI database alongside EPO patent searches. For pharma compounds and formulations where Swiss domestic filing supplements European patent strategy, missing the IPI layer means missing blocking patents that may have a different — and potentially longer — effective protection scope than the EPO-validated counterparts.
How SPC Extensions Work in Switzerland
What an SPC is: A Supplementary Protection Certificate (SPC) is a separate intellectual property right that extends the effective protection of a pharmaceutical or medtech patent beyond its standard 20-year term. SPCs exist to compensate patent holders for the time lost to regulatory approval processes — the period between the patent filing date and the date of first marketing authorisation for the product. In Switzerland, SPCs are governed by the Swiss Patent Act and can extend protection by up to five years.
Swiss SPC requirements: To obtain a Swiss SPC, a patent holder must hold an underlying patent that is still in force, have received a first marketing authorisation in Switzerland for the product covered by the patent, and file the SPC application within six months of either the patent grant or the marketing authorisation date, whichever is later. The SPC attaches to the underlying patent and expires at most five years after the patent’s normal expiry date. The product protected by the SPC must be the subject of a valid marketing authorisation.
How SPC expiry dates change the effective blocking timeline: For pharma FTO, the SPC expiry date — not the underlying patent expiry date — is the date that determines when the compound, formulation, or product covered by the SPC becomes available for generic or biosimilar market entry. A compound patent that appears to expire in 2026 may carry an SPC that extends effective protection to 2031. An FTO analysis that relies on patent expiry dates without checking SPC status will consistently underestimate the effective blocking period for products where SPCs are in force.
SPC CONTEXT: Switzerland has a distinct SPC system from the EU SPC Regulation. Swiss SPCs are granted by the IPI under Swiss national law. The validity requirements and the relationship between the SPC and the underlying marketing authorisation are governed by Swiss law, not EU law. For products that have EU marketing authorisation but separate Swiss marketing authorisation, the SPC analysis needs to be conducted under Swiss SPC rules rather than assuming equivalence with EU SPC outcomes.
SPC Validity as a Separate FTO Assessment
SPC validity is one of the most frequently overlooked dimensions of Swiss pharma FTO. Our analysis of the Swiss Federal Patent Court’s expedited nullity proceedings and their implications for pharma portfolios highlights that SPC validity is a separate question from underlying patent validity — both need to be assessed before proceedings commence, because a successful challenge to an SPC can open market entry even where the underlying patent remains valid.
Why SPC validity is not the same as underlying patent validity: A Swiss SPC can be invalid even if the underlying patent is valid and in force. SPC invalidity arises when the SPC was granted on the basis of a marketing authorisation that does not cover the product protected by the patent, when the underlying patent does not actually protect the product as required by the SPC rules, or when the SPC application was filed out of time. These are SPC-specific validity grounds that are entirely separate from the novelty, inventive step, and enablement grounds on which the underlying patent itself can be challenged.
Common SPC validity vulnerabilities: The most frequent SPC validity issues in Swiss pharma are: (1) the scope of the marketing authorisation does not align with the scope of the patent claims as required for SPC grant; (2) the patent does not protect the active ingredient as required by Swiss SPC rules; and (3) where the product received marketing authorisation in the EU before Switzerland, the Swiss SPC term calculation may contain errors. For each blocking SPC identified in the FTO, a validity pre-screen covering these SPC-specific grounds is a necessary step before treating the SPC as a solid blocking right.
How to assess SPC validity risk in an FTO context: A preliminary SPC validity assessment reviews the IPI’s SPC grant file, checks the scope alignment between the marketing authorisation product and the patent claims, verifies the SPC term calculation, and identifies whether any of the common SPC invalidity grounds apply. SPCs identified as potentially invalid on SPC-specific grounds are flagged as challenge candidates in the FTO output — giving the product team the information they need to decide whether to challenge the SPC or design around the protected product.
“The SPC that appears to block your Swiss market entry may be invalid on grounds entirely separate from the underlying patent. A blocking SPC with a scope alignment problem — where the marketing authorisation product does not match the patent claims as required by Swiss SPC rules — is challengeable in FPC nullity proceedings. The FTO that identifies this gives the product team an option the FTO that treats the SPC as unquestionable does not.”
Building a Complete Swiss Pharma FTO
- Cover both patent layers. Run separate searches on the EPO database (for patents validated in Switzerland) and the IPI database (for domestic Swiss patents). Do not assume that EPO patent coverage is comprehensive for the Swiss market. Identify all active patents in both databases that are relevant to the target product’s compound, formulation, manufacturing process, and therapeutic use.
- Identify all active SPCs for the target product category. Search the IPI’s SPC register for all active SPCs that could cover the target product or its active ingredient. Cross-reference the SPC register against the patent layer search to identify which blocking patents have active SPC extensions, and determine the SPC expiry date for each. The SPC expiry date — not the patent expiry date — is the effective market entry date for products covered by an active SPC.
- Assess SPC expiry dates and effective blocking periods. For each active blocking SPC, calculate the effective blocking period from today’s date to the SPC expiry date. Where the SPC expiry date is more than 12 months away, include the SPC in the blocking risk assessment at its full effective scope. Where the SPC expiry date is within 12 months, flag it as an approaching expiry that may open market entry within the commercial planning horizon.
- Assess SPC validity risk for each blocking SPC. For each active blocking SPC that represents a material commercial obstacle, conduct a preliminary SPC validity assessment covering scope alignment, patent-product correspondence, and SPC term calculation accuracy. SPCs with identified validity vulnerabilities are flagged as challenge candidates alongside the standard blocking risk assessment.
How Our FTO Service Covers Swiss Pharmaceutical Products
Our freedom to operate service covers Swiss pharmaceutical FTO across both patent layers — EPO-validated patents and domestic IPI patents — with separate SPC register search, SPC expiry date assessment, and preliminary SPC validity review for blocking SPCs. For generic manufacturers, biosimilar developers, and specialty pharma companies planning Swiss market entry, we structure the FTO to account for all three dimensions of Swiss pharma blocking IP: EPO patents, domestic IPI patents, and SPC extensions with their validity risk profiles. The output gives product teams the complete blocking IP picture — including the challenge opportunities that a two-layer patent search without SPC validity assessment would miss.
Japanese market FTO requires JPO-calibrated claim scope assessment, prosecution history review, and preliminary enablement analysis for broad functional claims. Our service covers all three — giving you a blocking risk picture that reflects Japanese enforcement standards, not US or EPO assumptions. → Contact Us
Conclusion: The Takeaway
Swiss pharmaceutical FTO is a three-dimension analysis: the EPO patent layer, the domestic IPI patent layer, and the SPC extension layer. Missing any one of the three produces an FTO that answers a narrower question than the one the product team actually needs answered. And within the SPC layer, validity assessment is a separate step from identifying active SPCs — because a blocking SPC may be invalid on grounds entirely separate from the underlying patent, and that invalidity is an option the FTO should surface.
The teams that get Swiss pharma FTO right are the ones that cover all three dimensions systematically — not because they are more thorough in general, but because they understand the specific structure of Swiss pharmaceutical IP protection. That structure is the starting point for FTO scope. Getting it right from the beginning is the only way to get the clearance picture that Swiss market entry requires.
